Lexicon Pharmaceuticals Inc (LXRX)
1.77
-0.07
(-3.80%)
USD |
NASDAQ |
May 17, 16:00
1.77
0.00 (0.00%)
After-Hours: 20:00
Lexicon Pharmaceuticals Cash from Financing (Quarterly): 239.38M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 239.38M |
December 31, 2023 | -0.001M |
September 30, 2023 | -0.21M |
June 30, 2023 | 189.00M |
March 31, 2023 | -0.824M |
December 31, 2022 | 24.91M |
September 30, 2022 | 94.02M |
June 30, 2022 | 0.00 |
March 31, 2022 | 23.28M |
December 31, 2021 | -11.32M |
September 30, 2021 | 19.78M |
June 30, 2021 | -0.023M |
March 31, 2021 | 14.27M |
December 31, 2020 | 64.15M |
September 30, 2020 | -210.12M |
June 30, 2020 | -0.425M |
March 31, 2020 | -1.244M |
December 31, 2019 | -0.322M |
September 30, 2019 | -0.32M |
June 30, 2019 | -0.322M |
March 31, 2019 | -1.262M |
December 31, 2018 | -0.139M |
September 30, 2018 | -0.356M |
June 30, 2018 | -0.221M |
March 31, 2018 | -1.528M |
Date | Value |
---|---|
December 31, 2017 | 147.84M |
September 30, 2017 | -0.498M |
June 30, 2017 | 3.69M |
March 31, 2017 | -1.104M |
December 31, 2016 | 0.16M |
September 30, 2016 | 1.684M |
June 30, 2016 | 0.071M |
March 31, 2016 | -0.928M |
December 31, 2015 | -0.471M |
September 30, 2015 | -0.353M |
June 30, 2015 | -0.378M |
March 31, 2015 | -0.83M |
December 31, 2014 | 285.66M |
September 30, 2014 | -0.266M |
June 30, 2014 | -0.36M |
March 31, 2014 | -1.231M |
December 31, 2013 | -0.112M |
September 30, 2013 | 0.022M |
June 30, 2013 | -0.288M |
March 31, 2013 | -1.011M |
December 31, 2012 | 36.82M |
September 30, 2012 | 0.407M |
June 30, 2012 | -0.129M |
March 31, 2012 | -0.722M |
December 31, 2011 | 160.25M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-210.12M
Minimum
Sep 2020
239.38M
Maximum
Mar 2024
22.18M
Average
-0.012M
Median
Cash from Financing (Quarterly) Benchmarks
Windtree Therapeutics Inc | 0.521M |
AIM ImmunoTech Inc | 0.147M |
Perspective Therapeutics Inc | 166.33M |
Protalix BioTherapeutics Inc | 0.00 |
Armata Pharmaceuticals Inc | 34.93M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -55.13M |
Cash from Investing (Quarterly) | -110.22M |
Free Cash Flow | -185.41M |
Free Cash Flow Per Share (Quarterly) | -0.2247 |
Free Cash Flow to Equity (Quarterly) | -55.50M |
Free Cash Flow Yield | -44.56% |